Zonal Difference and Prognostic Significance of Foxp3 Regulatory T Cell Infiltration in Breast Cancer

다국어 초록 (Multilingual Abstract)

Purpose: Forkhead box P3 (Foxp3) is known as the most specificmarker for regulatory T lymphocytes, which play an important rolein immune tolerance to disturb antitumor immunity. The presentstudy aimed to investigate the prognostic significance of Foxp3regulatory T lymphocyte (Foxp3 Treg) infiltration in breast cancer.
Methods: Immunohistochemical studies with Foxp3, CD4, andCD8 were performed on representative full tissue sections from143 patients with invasive ductal carcinoma, not otherwise specified.
Foxp3 Treg infiltration and the ratios between Foxp3 Tregand CD4 or CD8 T cells were separately analyzed for the tumorbed and tumor periphery to evaluate their association with differentclinicopathological parameters and patients’ outcome. Results:The tumor periphery was considerably more densely infiltratedby Foxp3 Treg, CD4, and CD8 T cells than the tumor bed.
Unfavorable clinicopathological parameters (a Ki-67 labeling indexof ≥14%, a worse histologic grade, a worse nuclear grade,hormone receptor negativity, human epidermal growth factor receptor2 positivity, and tumor recurrence) were associated withincreased Foxp3 Treg infiltration and a high ratio between Foxp3Treg and CD4/CD8 T cells. In the tumor periphery, as Foxp3 Treginfiltration and the Foxp3 Treg/CD8 ratio increased, patients’5-year disease-free survival rate decreased. Conclusion: The infiltrationdensities of Foxp3 Treg, CD4, and CD8 T cells weremarkedly different between the tumor bed and periphery. Besidesthe absolute count of Foxp3 Treg, the ratio between Foxp3Treg and effector T cells was a significant prognostic factor inbreast cancer.

참고문헌 (Reference)

1 강한나, "삼중음성유방암에서 Foxp3 양성 조절 T세포와 종양 침윤 T림프구의 의의" 대한병리학회 45 (45): 53-61, 2011

2 Salama P, "Tumorinfiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer" 27 : 186-192, 2009

3 Amedei A, "T cells in gastric cancer: friends or foes" 2012 : 690571-, 2012

4 Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer. Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011" 22 : 1736-1747, 2011

5 Zou W, "Regulatory T cells, tumour immunity and immunotherapy" 6 : 295-307, 2006

6 Gobert M, "Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome" 69 : 2000-2009, 2009

7 Nishikawa H, "Regulatory T cells in tumor immunity" 127 : 759-767, 2010

8 Beyer M, "Regulatory T cells in cancer" 108 : 804-811, 2006

9 Bates GJ, "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse" 24 : 5373-5380, 2006

10 Hiraoka N, "Prevalence of FOXP3+regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions" 12 : 5423-5434, 2006

11 Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up" 19 : 403-410, 1991

12 Sakaguchi S, "Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self" 6 : 345-352, 2005

13 Khong HT, "Natural selection of tumor variants in the generation of “tumor escape” phenotypes" 3 : 999-1005, 2002

14 Curti A, "Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells" 109 : 2871-2877, 2007

15 Shevach EM, "Mechanisms of foxp3+ T regulatory cell-mediated suppression" 30 : 636-645, 2009

16 Mizukami Y, "Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer" 98 : 148-153, 2008

17 Bohling SD, "Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target" 21 : 1527-1532, 2008

18 Garín MI, "Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells" 109 : 2058-2065, 2007

19 Fontenot JD, "Foxp3 programs the development and function of CD4+CD25+ regulatory T cells" 4 : 330-336, 2003

20 Sakaguchi S, "FOXP3+ regulatory T cells in the human immune system" 10 : 490-500, 2010

21 Kobayashi N, "FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis" 13 : 902-911, 2007

22 Hori S, "Control of regulatory T cell development by the transcription factor Foxp3" 299 : 1057-1061, 2003

23 Liu F, "CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes" 130 : 645-655, 2011

24 Antony PA, "CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells" 174 : 2591-2601, 2005

25 Pandiyan P, "CD4+CD25+Foxp3+regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells" 8 : 1353-1362, 2007

26 Ghiringhelli F, "CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative" 34 : 336-344, 2004

27 DiPaolo RJ, "CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells" 175 : 7135-7142, 2005

28 Hammond ME, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer" 28 : 2784-2795, 2010

29 Wolff AC, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer" 25 : 118-145, 2007